{"id":"docetaxel-cisplatin-control","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Neutropenia"},{"rate":"40–60","effect":"Anemia"},{"rate":"20–40","effect":"Thrombocytopenia"},{"rate":"40–60","effect":"Nausea/vomiting"},{"rate":"20–40","effect":"Peripheral neuropathy"},{"rate":"10–20","effect":"Nephrotoxicity"},{"rate":"5–10","effect":"Ototoxicity"},{"rate":"50–80","effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL197201","moleculeType":"Small molecule","molecularWeight":"520.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel stabilizes microtubules and prevents their disassembly, disrupting mitotic spindle formation and cell division. Cisplatin forms DNA cross-links, causing DNA damage and triggering apoptosis. Together, these agents provide synergistic cytotoxic activity against rapidly dividing cancer cells. This is a control arm in a phase 3 trial, likely comparing against a newer regimen or immunotherapy combination.","oneSentence":"This combination uses docetaxel (a microtubule-stabilizing taxane) and cisplatin (a platinum-based DNA-damaging agent) to inhibit cell division and induce apoptosis in lung cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:38.062Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC), advanced or metastatic"}]},"trialDetails":[{"nctId":"NCT07402538","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Oral Cancer, Oropharyngeal Cancer","enrollment":184},{"nctId":"NCT06952621","phase":"PHASE3","title":"Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":390},{"nctId":"NCT07358689","phase":"PHASE2","title":"Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":"NSCLC","enrollment":120},{"nctId":"NCT05494190","phase":"NA","title":"The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-11-01","conditions":"Hypopharyngeal Carcinoma","enrollment":111},{"nctId":"NCT01927744","phase":"PHASE2","title":"Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-16","conditions":"Head and Neck Cancer","enrollment":55},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":"Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy","enrollment":29},{"nctId":"NCT04909164","phase":"","title":"The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2021-06-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":1500},{"nctId":"NCT06861712","phase":"PHASE2","title":"Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-06","conditions":"Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT)","enrollment":50},{"nctId":"NCT05508347","phase":"PHASE2","title":"Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-04-20","conditions":"Nasopharyngeal Carcinoma","enrollment":170},{"nctId":"NCT06737822","phase":"PHASE3","title":"Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers:","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Jodhpur","startDate":"2024-12-20","conditions":"Oral Cancer, Head and Neck Neoplasms","enrollment":346},{"nctId":"NCT03632798","phase":"PHASE3","title":"Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Cordgenics, LLC","startDate":"2018-08-01","conditions":"Recurrent Ovarian Cancer","enrollment":""},{"nctId":"NCT00478699","phase":"PHASE3","title":"Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2007-06","conditions":"Non-small-cell Lung Cancer","enrollment":500},{"nctId":"NCT05173987","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-02-03","conditions":"Endometrial Neoplasms","enrollment":280},{"nctId":"NCT04723875","phase":"PHASE3","title":"Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2021-01-28","conditions":"Uterine Cervical Neoplasms, Cervical Cancer","enrollment":306},{"nctId":"NCT03904927","phase":"PHASE2","title":"Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2019-02-01","conditions":"Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma","enrollment":104},{"nctId":"NCT06137378","phase":"PHASE2","title":"European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2024-04-17","conditions":"Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III","enrollment":140},{"nctId":"NCT04664972","phase":"PHASE2","title":"Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2018-11-23","conditions":"Triple Negative Breast Cancer","enrollment":212},{"nctId":"NCT03949283","phase":"PHASE3","title":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cordgenics, LLC","startDate":"2019-07-26","conditions":"Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer","enrollment":150},{"nctId":"NCT06542549","phase":"PHASE3","title":"Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-10-01","conditions":"Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy","enrollment":100},{"nctId":"NCT04931420","phase":"PHASE2","title":"Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-05-19","conditions":"Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma","enrollment":""},{"nctId":"NCT01064479","phase":"PHASE2","title":"Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-02-05","conditions":"Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity","enrollment":123},{"nctId":"NCT04158440","phase":"PHASE3","title":"Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-04-07","conditions":"Stage II-III Non-small Cell Lung Cancer","enrollment":501},{"nctId":"NCT02923258","phase":"PHASE2, PHASE3","title":"Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2018-04-21","conditions":"Oral Cavity Squamous Cell Carcinoma","enrollment":224},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT02889666","phase":"PHASE1","title":"A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2008-01","conditions":"Recurrent Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT03326947","phase":"PHASE2","title":"Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-01-01","conditions":"Neoplasm Neck","enrollment":60},{"nctId":"NCT00617656","phase":"PHASE3","title":"Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma","status":"TERMINATED","sponsor":"Spanish Lung Cancer Group","startDate":"2008-02","conditions":"Non Small Cell Lung Cancer, BRCA1 Mutation","enrollment":382},{"nctId":"NCT02290145","phase":"PHASE2","title":"Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-12","conditions":"Mouth Neoplasms, Carcinoma, Squamous Cell","enrollment":48},{"nctId":"NCT02285543","phase":"PHASE2","title":"A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients","status":"TERMINATED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-12-01","conditions":"Mouth Neoplasms, Carcinoma, Squamous Cell","enrollment":10},{"nctId":"NCT03734952","phase":"NA","title":"Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2023-05-01","conditions":"Radiation Oncology","enrollment":537},{"nctId":"NCT02285530","phase":"PHASE2","title":"GDF15 Based TPF Induction Chemotherapy for OSCC Patients","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2019-12-01","conditions":"Mouth Neoplasms, Carcinoma, Squamous Cell","enrollment":72},{"nctId":"NCT05481775","phase":"PHASE2","title":"Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2022-04-01","conditions":"Locally Advanced Non-small Cell Lung Cancer, Efficacy and Safety","enrollment":""},{"nctId":"NCT05622474","phase":"NA","title":"A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-11-30","conditions":"Nasopharyngeal Carcinoma","enrollment":236},{"nctId":"NCT05461261","phase":"PHASE2","title":"The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-07-01","conditions":"Hormone Sensitive Metastatic Prostate Cancer, DNA Damage Repair Deficiency, Chemotherapy Effect","enrollment":50},{"nctId":"NCT05569668","phase":"","title":"Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2021-01-01","conditions":"Esophagus Cancer","enrollment":826},{"nctId":"NCT02268695","phase":"PHASE2","title":"Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2014-10-10","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":541},{"nctId":"NCT04849377","phase":"PHASE2","title":"RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC","status":"WITHDRAWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-06-14","conditions":"Human Papillomavirus (HPV), Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":""},{"nctId":"NCT05246020","phase":"PHASE2","title":"Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial)","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-12-01","conditions":"Hyperthermic Intraperitoneal Chemotherapy, Neoadjuvant Chemotherapy","enrollment":80},{"nctId":"NCT02512315","phase":"PHASE3","title":"A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Nasopharyngeal Carcinoma","enrollment":192},{"nctId":"NCT03580395","phase":"PHASE2, PHASE3","title":"Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2017-06-01","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT04772287","phase":"PHASE3","title":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-03-31","conditions":"Non Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT04766827","phase":"PHASE4","title":"Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2020-12-12","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":116},{"nctId":"NCT02577341","phase":"PHASE2","title":"Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Non-small-cell Lung Cancer","enrollment":122},{"nctId":"NCT04733820","phase":"PHASE3","title":"Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2021-02-01","conditions":"Uterine Cervical Neoplasms, Cervical Cancer","enrollment":340},{"nctId":"NCT04595929","phase":"NA","title":"Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2020-02-10","conditions":"Peritoneal Carcinomatosis, Gastric Cancer","enrollment":304},{"nctId":"NCT04138992","phase":"PHASE2, PHASE3","title":"A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2020-08-01","conditions":"Disease Free Survival","enrollment":150},{"nctId":"NCT04414566","phase":"PHASE3","title":"Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":562},{"nctId":"NCT02076477","phase":"PHASE3","title":"The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2014-01","conditions":"Oligo-metastatic Stage IV Non-small Cell Lung Cancer","enrollment":420},{"nctId":"NCT01312350","phase":"PHASE2","title":"Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-11","conditions":"Hypopharyngeal Cancer","enrollment":40},{"nctId":"NCT03373058","phase":"PHASE3","title":"Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery","status":"UNKNOWN","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2019-10-15","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":310},{"nctId":"NCT02721563","phase":"PHASE4","title":"A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC","status":"COMPLETED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-02-25","conditions":"Esophageal Neoplasms","enrollment":77},{"nctId":"NCT01967875","phase":"PHASE2","title":"A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer","status":"TERMINATED","sponsor":"China Medical University, China","startDate":"2013-07","conditions":"Stomach Neoplasms","enrollment":27},{"nctId":"NCT03932266","phase":"PHASE2","title":"Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2019-06","conditions":"Nasopharyngeal Carcinoma","enrollment":73},{"nctId":"NCT03799601","phase":"PHASE4","title":"Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2019-03-01","conditions":"NSCLC","enrollment":45},{"nctId":"NCT03692780","phase":"PHASE1, PHASE2","title":"Careseng 1370 for Chemotherapy-Induced Myelosuppression","status":"WITHDRAWN","sponsor":"Careseng Biotech Co., Ltd.","startDate":"2019-03","conditions":"Chemotherapy-Induced Myelosuppression","enrollment":""},{"nctId":"NCT03723343","phase":"","title":"GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-10-18","conditions":"Advanced Nasopharyngeal Carcinoma","enrollment":146},{"nctId":"NCT00454779","phase":"PHASE2","title":"PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-01-01","conditions":"Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck","enrollment":113},{"nctId":"NCT03604965","phase":"PHASE3","title":"GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-07-21","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":204},{"nctId":"NCT03574324","phase":"PHASE3","title":"TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-05-24","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":266},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT03061058","phase":"PHASE3","title":"Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2013-04-01","conditions":"Stomach Neoplasms, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":240},{"nctId":"NCT03117257","phase":"PHASE2","title":"Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2016-08-19","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":144},{"nctId":"NCT02088515","phase":"PHASE4","title":"Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2013-12","conditions":"Squamous Cell Carcinoma","enrollment":290},{"nctId":"NCT01665417","phase":"PHASE4","title":"Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2012-08","conditions":"EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma","enrollment":100},{"nctId":"NCT03006614","phase":"PHASE3","title":"PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shi Yanxia","startDate":"2016-04","conditions":"Breast Cancer Model, Effects of Chemotherapy, Breast Cancer","enrollment":320},{"nctId":"NCT03002064","phase":"PHASE3","title":"Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-12","conditions":"Esophagus Cancer, Chemotherapy Effects","enrollment":358},{"nctId":"NCT02969473","phase":"PHASE2","title":"Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Zhu Yujia","startDate":"2010-10","conditions":"Esophageal Neoplasm, Chemoradiation","enrollment":120},{"nctId":"NCT00190476","phase":"PHASE3","title":"Elderly NSCLC/D vs DP (JCOG0207)","status":"TERMINATED","sponsor":"Japan Clinical Oncology Group","startDate":"2003-04","conditions":"Non-small-cell Lung Cancer","enrollment":230},{"nctId":"NCT02610556","phase":"PHASE2","title":"Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Nasopharyngeal Carcinoma","enrollment":130},{"nctId":"NCT02031601","phase":"PHASE4","title":"Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2014-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":250},{"nctId":"NCT02703961","phase":"PHASE3","title":"Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2016-02","conditions":"Cervical Cancer","enrollment":598},{"nctId":"NCT02701231","phase":"NA","title":"Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-11","conditions":"Lung Neoplasms","enrollment":200},{"nctId":"NCT01263886","phase":"PHASE2","title":"Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-02","conditions":"Non-small Cell Lung Cancer","enrollment":176},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT02061631","phase":"PHASE2","title":"Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-05","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":35},{"nctId":"NCT02513342","phase":"PHASE4","title":"Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma","status":"UNKNOWN","sponsor":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","startDate":"2015-03","conditions":"Advanced Lung Squamous Carcinoma","enrollment":400},{"nctId":"NCT01829178","phase":"PHASE2, PHASE3","title":"Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2013-08","conditions":"Upper GI Cancer, Cisplatin Adverse Reaction","enrollment":30},{"nctId":"NCT02353260","phase":"PHASE2","title":"Efficacy and Safety of Ultrasound Hyperthermia Combined With Chemotherapy on Oral and Maxillofacial-Head and Neck Cancer","status":"UNKNOWN","sponsor":"Wei Guo","startDate":"2014-12","conditions":"Head and Neck Cancer","enrollment":120},{"nctId":"NCT01038661","phase":"PHASE3","title":"Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-11","conditions":"Lung Neoplasms","enrollment":375},{"nctId":"NCT01977209","phase":"PHASE3","title":"Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2013-09","conditions":"Non-small Cell Lung Cancer","enrollment":204},{"nctId":"NCT00771563","phase":"PHASE3","title":"Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2008-06","conditions":"Non-Small Cell Lung Cancer","enrollment":104},{"nctId":"NCT01283217","phase":"PHASE3","title":"Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2010-03","conditions":"Gastric Adenocarcinoma","enrollment":166},{"nctId":"NCT00525200","phase":"PHASE3","title":"p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer","status":"COMPLETED","sponsor":"Daniela Kandioler","startDate":"2007-06","conditions":"Esophageal Cancer","enrollment":170},{"nctId":"NCT01560195","phase":"PHASE3","title":"A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2012-04","conditions":"NSCLC, Neutropenia, Febrile Neutropenia","enrollment":150},{"nctId":"NCT00261703","phase":"PHASE2, PHASE3","title":"Docetaxel in Head and Neck Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-12","conditions":"Head and Neck Neoplasms","enrollment":439},{"nctId":"NCT01192230","phase":"PHASE2","title":"Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2009-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT00070629","phase":"PHASE2","title":"CPG 7909 Injection in Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-05","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taxotere/Platinol"],"phase":"phase_3","status":"active","brandName":"Docetaxel/Cisplatin control","genericName":"Docetaxel/Cisplatin control","companyName":"Spanish Lung Cancer Group","companyId":"spanish-lung-cancer-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses docetaxel (a microtubule-stabilizing taxane) and cisplatin (a platinum-based DNA-damaging agent) to inhibit cell division and induce apoptosis in lung cancer cells. Used for Non-small cell lung cancer (NSCLC), advanced or metastatic.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}